Application of 13C CPMAS NMR for qualitative and quantitative characterization of carvedilol and its commercial formulations

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1763-1772

  Zielińska pisklak, Monika ^a   Pisklak, Dariusz Maciej ^a   Wawer, Iwona ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Excipients; Formulation; Solid dosage form; Solid state NMR; Tablet

Indexed keywords

CARBON 13; CARVEDIGAMMA 25; CARVEDILOL; CARVEDILOL RATIOPHARM 25; CARVEDILOL TEVA 25; CORYOL 25; DILATREND 25; EXCIPIENT; UNCLASSIFIED DRUG; VIVACOR 25; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARBON; PROPANOLAMINE DERIVATIVE;

ARTICLE; CARBON CROSS POLARIZATION MAGIC ANGLE SPINNING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MANUFACTURE; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLARIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SOLID STATE; TABLET FORMULATION; CHEMISTRY; METHODOLOGY;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CARBON ISOTOPES; CHEMISTRY, PHARMACEUTICAL; MAGNETIC RESONANCE SPECTROSCOPY; PROPANOLAMINES;

EID: 84864292570     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23062     Document Type: Article

References (22)

1. Blagden N, de Matas M, Gavan PT, York P. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility. Adv Drug Dev 59:617-630.
2. Tian F, Sandler N, Aaltonen J, Lang C, Saville DJ, Gordon KC, Strachan CJ, Rantanen J, Rades T. 2007. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J Pharm Sci 96:584-594.
3. Kobayashi Y, Ito S, Itai S, Yamamoto K. 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dehydrate. Int J Pharm 193:137-146.
4. Yu L. 2001. Amorphous pharmaceuticals solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
5. 15N NMR analysis of sildenafil base and citrate (Viagra) in solution, solid state and pharmaceutical dosage forms. J Pharm Biomed Anal 38:865-870.
6. Vickery RD, Nemeth GA, Maurin MB. 2002. Solid-state carbon NMR characterization of the polymorphs of roxifiban. J Pharm Biomed Anal 30:125-129.
7. Smith JR, Xu W, Raftery D. 2006. Analysis of conformational polymorphism in pharmaceutical solids using solid-state NMR and electronic structure calculations. J Phys Chem B 110:7766-7776.
8. Yates JR, Dobbins SE, Pickard CJ, Mauri F, Ghi PY, Harris RK. 2005. A combined first principles computational and solid-state NMR study of a molecular crystal: Flurbiprofen. Phys Chem Chem Phys 7:1402-1407.
9. Virtanen T, Maunu SL. 2010. Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state (13)C CPMAS NMR spectroscopy. Int J Pharm 394:18-25.
10. Harris RK, Hodgkinson P, Larsson T, Muruganantham A. 2005. Quantification of bambuterol hydrochloride in a formulated product using solid-state NMR. J Pharm Biomed Anal 38:858-864.
11. Harris RK. 2006. NMR studies of organic polymorphs and solvates. Analyst 131:351-373.
12. Geppi M, Mollica G, Borsacchi S, Veracini CA. 2008. Solid-state NMR studies of pharmaceutical systems. Appl Spectrosc Rev 43:202-302.
13. Holzgrabe U, Wawer I, Diehl B. 2008. NMR spectroscopy in pharmaceutical analysis. 1sted. Amsterdam: Elsevier.
14. Sotthivirat S, Lubach JW, Haslam JL, Munson EJ, Stella VJ. 2007. Characterization of prednisolone in controlled porosity osmotic pump pellets using solid-state NMR spectroscopy. J Pharm Sci 96:1008-1017.
15. Metra M, Dei Cas L, di Lenarda A, Poole-Wilson P. 2004. Beta-blockers in heart failure: Are pharmacological differences clinically important? Heart Fail Rev 9:123-130.
16. Vogt FG, Copley RCB, Mueller RL, Spoors GP, Cacchio TN, Carlton RA, Katrincic LM, Kennady JM, Parsons S, Chetina OV. 2010. Isomorphism, disorder, and hydration in the crystal structures of racemic and single-enantiomer carvedilol phosphate. Cryst Growth Des 10:2713-2733.
17. Yathirajan HS, Bindya S, Sreevidya TV, Narayana B, Bolte M. 2007. A second polymorph of carvedilol. Acta Cryst E63:o542-o544.
18. Chen WM, Zeng LM, Yu KB, Xu JH. 1998. Synthesis and crystal structure of carvedilol. Chin J Struct Chem 17:325-328.
19. Opella SJ, Frey MH. 1979. Selection of nonprotonated carbon resonances in solid-state nuclear magnetic resonance. J Am Chem Soc 101:5854-5856.
20. 13C NMR characteristics of β-blockers. Magn Reson Chem 49:284-290.
21. Malz F, Jancke H. 2005. Validation of quantitative NMR. J Pharm Biomed Anal 38:813-823.
22. 13C CPMAS NMR spectroscopy. J Pharm Sci 94:2591-2605.